Barriers in access to oncology drugs — a global crisis

1335P Using adaptive health technology assessment (aHTA) to assess the potential cost-effectiveness of pembrolizumab and palbociclib in the Indian context

(2022) M. Sengar et al.   ANNALS OF ONCOLOGY

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

(2021) Phyllis Ocran Mattila et al.   Frontiers in Public Health

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

(2021) Adam Fundytus et al.   LANCET ONCOLOGY

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

(2021) Kerstin N. Vokinger et al.   JAMA Oncology

Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China

(2021) Jing Yuan et al.   BMJ Global Health

Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review

(2021) Kristina Medlinskiene et al.   BMC HEALTH SERVICES RESEARCH

Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward

(2021) Carlos H Barrios et al.   LANCET ONCOLOGY

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe

(2020) Krzysztof Piotr Malinowski et al.   Orphanet Journal of Rare Diseases

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

(2020) Aneta Mela et al.   Frontiers in Pharmacology

The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: Overcoming the challenges of stewardship and governance

(2019) Blake J. Angell et al.   PLOS MEDICINE

Medical Bankruptcy: Still Common Despite the Affordable Care Act

(2019) David U. Himmelstein et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Patent pooling to increase access to essential medicines

(2019) Esteban Burrone et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists

(2019) Jordan D. Jarvis et al.   PLoS One

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment

(2018) Pricivel M. Carrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

(2018) Pedro N. Aguiar et al.   JAMA Oncology

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

(2018) L. Kandolf Sekulovic et al.   EUROPEAN JOURNAL OF CANCER

A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

(2017) Daniel A. Goldstein et al.   Oncotarget

Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes

(2016) Lawrence N. Shulman et al.   JOURNAL OF CLINICAL ONCOLOGY

Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries

(2015)   BMC Medicine

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?

(2014) G.F. Ho et al.   EUROPEAN JOURNAL OF CANCER

Delivery of affordable and equitable cancer care in India

(2014) C S Pramesh et al.   LANCET ONCOLOGY

The High Cost of Cancer Drugs and What We Can Do About It

(2012) Mustaqeem Siddiqui et al.   MAYO CLINIC PROCEEDINGS